GlassScriptPhysician profile
John M Odowd
NPI 1821089038
$7,256.11
in general payments reported to CMS, 2019-2025
35 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2020: $775 · 2021: $1,409 · 2022: $1,818 · 2023: $877 · 2024: $374 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,835.90 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $1,434.07 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $794.40 | 2019-2024 | Lifevest |
| Pfizer INC. | $770.20 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $522.01 | 2019-2022 | |
| Amgen INC. | $252.74 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.63 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $197.03 | 2019-2023 | Wainua, Farxiga |
| Sanofi-Aventis U.S. LLC | $186.80 | 2019-2023 | |
| Boston Scientific Corporation | $149.11 | 2019-2024 | |
| Altathera Pharmaceuticals LLC | $139.12 | 2021 | |
| Davol INC. | $82.30 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.27 | 2021 | |
| Merck Sharp & Dohme LLC | $67.20 | 2021-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $59.18 | 2021-2025 | Amvuttra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $52.86 | 2024 | Arcalyst |
| Baxter Healthcare | $45.88 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Atricure, INC. | $45.64 | 2022-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $42.02 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $38.61 | 2023-2025 | Nexletol |
| Scpharmaceuticals INC. | $34.70 | 2023-2025 | |
| Philips North America LLC | $31.62 | 2019 | |
| Amarin Pharma, INC. | $17.98 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.57 | 2019 | |
| Cardiovascular Systems INC. | $16.59 | 2022 | |
| Elutia, INC. | $15.95 | 2025 | Ecm Patch,Pouch |
| Medtronic, INC. | $15.95 | 2021 | |
| Novo Nordisk INC | $13.32 | 2019 | |
| Irhythm Technologies, INC. | $12.90 | 2023 | Zio Xt Patch |
| Abbott Laboratories | $12.47 | 2021 | |
| Portola Pharmaceuticals, LLC | $12.39 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.17 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.85 | 2019 | |
| Medtronic Vascular, INC. | $11.78 | 2020 | |
| Zoll Circulation INC | $4.90 | 2023 | Catheter, Therox Ds2 Console, Downstream Cartridge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Odowd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.